← Leaderboards
Paul S Knoepfler
Fred Hutchinson Cancer Research Center
$5,667,040
Attributed
$5,667,040
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $765.8K · FY2005–22$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$5,667,040 · 4
By mechanism
R01$4,947,351 · 3
K01$719,689 · 1
Top collaborators
No co-investigators on record.
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- Robert Neil Eisenman$37,903,199
- Pei Wang$7,634,998
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsBaseMalignant NeoplasmsInduced Pluripotent Stem CellGenesEpigenetic ProcessInnovationInsightLinkLoss Of FunctionFamilyMediatingStem CellsHistonesTumorGene TargetingBiological ModelsResearch PersonnelCrispr/Cas TechnologySignal TransductionMutationHistone H3Clustered Regularly Interspaced Short Palindromic RepeatsMultidisciplinary
Grant awards (21)
Targeting the Mutant H3.3 Pathway in Glioma$434,176
R01 · FY2022 · NS · contact PI
Targeting the Mutant H3.3 Pathway in Glioma$434,176
R01 · FY2021 · NS · contact PI
Targeting the Mutant H3.3 Pathway in Glioma$442,594
R01 · FY2020 · NS · contact PI
Targeting the Mutant H3.3 Pathway in Glioma$445,833
R01 · FY2019 · NS · contact PI
Targeting a novel H3.3 epigenetic switch to regulate health and disease$319,957
R01 · FY2019 · GM · contact PI
Targeting a novel H3.3 epigenetic switch to regulate health and disease$385,488
R01 · FY2018 · GM · contact PI
Targeting the Mutant H3.3 Pathway in Glioma$332,496
R01 · FY2018 · NS · contact PI
Targeting a novel H3.3 epigenetic switch to regulate health and disease$314,000
R01 · FY2017 · GM · contact PI
Targeting a novel H3.3 epigenetic switch to regulate health and disease$65,531
R01 · FY2017 · GM · contact PI
Targeting a Novel H3.3 Epigenetic Switch to Regulate Health and Disease$22,573
R01 · FY2017 · GM · contact PI
Targeting a novel H3.3 epigenetic switch to regulate health and disease$314,000
R01 · FY2016 · GM · contact PI
Myc Regulation of Embryonic Stem Cell Self-Renewal and Pluripotency$289,520
R01 · FY2015 · GM · contact PI
Myc Regulation of Embryonic Stem Cell Self-Renewal and Pluripotency$289,520
R01 · FY2014 · GM · contact PI
Myc Regulation of Embryonic Stem Cell Self-Renewal and Pluripotency$279,387
R01 · FY2013 · GM · contact PI
Myc Regulation of Embryonic Stem Cell Self-Renewal and Pluripotency$289,520
R01 · FY2012 · GM · contact PI
Myc Regulation of Embryonic Stem Cell Self-Renewal and Pluripotency$288,580
R01 · FY2011 · GM · contact PI
Analyzing Myc function in neural cancers and development$154,780
K01 · FY2009 · CA · contact PI
Analyzing Myc function in neural cancers and development$154,780
K01 · FY2008 · CA · contact PI
Analyzing Myc function in neural cancers and development$154,780
K01 · FY2007 · CA · contact PI
Analyzing Myc function in neural cancers and development$154,780
K01 · FY2006 · CA · contact PI
Analyzing Myc function in neural cancers and development$100,569
K01 · FY2005 · CA